Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Science Translational Medicine

• Publication date

  2016-11-23

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1126/scitranslmed.aaf8463PMID 27881823
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

  2016cited by this paper
• The microglial ATP‐gated ion channel P2X7 as a CNS drug target

  2016cited by this paper
• Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation

  2016cited by this paper
• A Novel Flow Cytometric Method To Assess Inflammasome Formation

  2015cited by this paper
• Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study

  2015cited by this paper
• A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.

  2015cited by this paper
• The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

  2015cited by this paper
• A rare P 2 X 7 variant Arg 307 Gln with absent pore formation function protects against neuroin fl ammation in multiple sclerosis

  2015cited by this paper
• A novel platform for engineering blood‐brain barrier‐crossing bispecific biologics

  2014cited by this paper
• P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders.

  2014cited by this paper
• Technical Advance: A new cell preparation strategy that greatly improves the yield of vital and functional Tregs and NKT cells

  2014cited by this paper
• The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response

  2014cited by this paper
• Nucleotide signalling during inflammation

  2014cited by this paper
• The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease

  2014influential reference
• Antibody therapeutics targeting ion channels: are we there yet?

  2013cited by this paper
• Nanobodies: natural single-domain antibodies.

  2013cited by this paper
• Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms

  2013cited by this paper
• Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine

  2012cited by this paper
• Cell‐penetrating anti‐GFAP VHH and corresponding fluorescent fusion protein VHH‐GFP spontaneously cross the blood‐brain barrier and specifically recognize astrocytes: application to brain imaging

  2012cited by this paper
• Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors

  2012cited by this paper
• Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors

  2012cited by this paper
• Efficacy and Safety of CE-224,535, an Antagonist of P2X7 Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate

  2012cited by this paper
• Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity

  2012cited by this paper
• Gain-of-function of P2X7 receptor gene variants in multiple sclerosis.

  2011cited by this paper
• A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases

  2011cited by this paper
• Nephrotic Syndrome and Subepithelial Deposits in a Mouse Model of Immune-Mediated Anti-Podocyte Glomerulonephritis

  2011influential reference
• Lack of the purinergic receptor P2X7 results in resistance to contact hypersensitivity

  2010influential reference
• P2X7 deficiency attenuates renal injury in experimental glomerulonephritis.

  2009cited by this paper
• Single domain antibodies: promising experimental and therapeutic tools in infection and immunity

  2009cited by this paper
• General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold*

  2009cited by this paper
• NAD+ and ATP Released from Injured Cells Induce P2X7-Dependent Shedding of CD62L and Externalization of Phosphatidylserine by Murine T Cells1

  2009cited by this paper
• Transient expression and purification of chimeric heavy chain antibodies.

  2009cited by this paper
• Genetics of the P2X7 receptor and human disease

  2009cited by this paper
• Antagonists of the P2X(7) receptor. From lead identification to drug development.

  2009cited by this paper
• The development of nanobodies for therapeutic applications.

  2009cited by this paper
• Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

  2008influential reference
• Selective P2X7 receptor antagonists for chronic inflammation and pain

  2008cited by this paper
• ADP‐ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site

  2008cited by this paper
• Single domain antibodies from llama effectively and specifically block T cell ecto‐ADP‐ribosyltransferase ART2.2 in vivo

  2007cited by this paper
• Monitoring the expression of purinoceptors and nucleotide-metabolizing ecto-enzymes with antibodies directed against proteins in native conformation

  2007cited by this paper
• Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies.

  2006cited by this paper
• The P2X7 Receptor: A Key Player in IL-1 Processing and Release1

  2006cited by this paper
• P2X receptors as cell-surface ATP sensors in health and disease

  2006cited by this paper
• Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis.

  2006cited by this paper
• The P2X7 Receptor: A Key Player in IL-1 Processing and Release

  2006cited by this paper
• Pannexin‐1 mediates large pore formation and interleukin‐1β release by the ATP‐gated P2X7 receptor

  2006cited by this paper
• Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain

  2005cited by this paper
• A Novel P2X7 Receptor Activator, the Human Cathelicidin-Derived Peptide LL37, Induces IL-1β Processing and Release1

  2004cited by this paper
• NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor.

  2003cited by this paper
• Absence of the P2X7 Receptor Alters Leukocyte Function and Attenuates an Inflammatory Response

  2002cited by this paper
• Blockade of human P2X7 receptor function with a monoclonal antibody.

  1998cited by this paper

• pH-Responsive Supramolecular System for Activation of Cellular Calcium Channels.

  2026cites this paper
• Nanobodies for inflammatory bowel disease: Miniaturizing solutions.

  2026cites this paper
• A modified single-domain antibody candidate for the treatment of botulism caused by botulinum toxin type A

  2025cites this paper
• Modulating ion channels with nanobodies

  2025cites this paper
• Resident T Cells and Intrarenal Inflammation.

  2025cites this paper
• The Purinoreceptor P2X7 in Extracellular ATP-Mediated Inflammation through the Spectrum of Kidney Diseases and Kidney Transplantation.

  2025cites this paper
• Pure drug nanomedicines - where we are?

  2025cites this paper
• Nanobody-based Pannexin1 channel inhibitors increase survival after cardiac ischemia/reperfusion

  2025cites this paper
• Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy

  2025cites this paper
• From Selective Permeation to Physiology in Potassium Channels

  2025cites this paper
• A multivalent nanobody–drug conjugate to prevent and treat influenza virus infections

  2025cites this paper
• Adeno‐associated viral vectors encoding anti‐P2X7 nanobodies reduce graft‐versus‐host disease in a humanised mouse model

  2025cites this paper
• Harnessing single-domain antibodies for CAR-T and bispecific antibody development.

  2025cites this paper
• Purinergic adipocyte-macrophage crosstalk promotes degeneration of thermogenic brown adipose tissue

  2025influential citation
• Nanobodies targeting ion channels: advancing therapeutics through precision and structural insights.

  2025cites this paper
• Future Directions and Pipeline Therapies for Hidradenitis Suppurativa.

  2025cites this paper
• Injection of ROS-Responsive Hydrogel Loaded with IL-1β-targeted nanobody for ameliorating myocardial infarction

  2024cites this paper
• ATP-Gated P2X7-Ion Channel on Kidney-Resident Natural Killer T Cells and Memory T Cells in Intrarenal Inflammation

  2024influential citation
• Purinergic-associated immune responses in neurodegenerative diseases.

  2024cites this paper
• Constitutive DAMPs in CNS injury: From preclinical insights to clinical perspectives.

  2024cites this paper
• Nanobody‐based heavy chain antibodies and chimeric antibodies

  2024cites this paper
• The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy

  2024cites this paper
• Generation of nanobodies from transgenic ‘LamaMice’ lacking an endogenous immunoglobulin repertoire

  2024cites this paper
• Generation and characterization of antagonistic anti-human CD39 nanobodies

  2024cites this paper
• Development of Shark Single Domain Antibodies Specific for Human α-Fetoprotein and the Multimerization Strategy in Serum Detection.

  2024cites this paper
• Administration of an AAV vector coding for a P2X7-blocking nanobody-based biologic ameliorates colitis in mice

  2024influential citation
• Application of nanotechnology in the treatment of glomerulonephritis: current status and future perspectives

  2024cites this paper
• Skin-interfaced electronics: A promising and intelligent paradigm for personalized healthcare.

  2023cites this paper
• Taurodeoxycholate, a GPCR19 agonist, ameliorates atopic dermatitis in Balb/c mice

  2023cites this paper
• Polyvalency: An emerging trend in the development of clinical antibodies.

  2023cites this paper
• Nanobodies in cell-mediated immunotherapy: On the road to fight cancer

  2023cites this paper
• Enhanced in vivo blood brain barrier transcytosis of macromolecular cargo using an engineered pH-sensitive mouse transferrin receptor binding nanobody

  2023cites this paper
• A Species-Specific Anti-Human P2X7 Monoclonal Antibody Reduces Graft-versus-Host Disease in Humanised Mice

  2023cites this paper
• Synthetic molecules as P2X7 receptor antagonists: A medicinal chemistry update focusing the therapy of inflammatory diseases.

  2023cites this paper
• SINGLE-DOMAIN ANTIBODIES APPLIED AS ANTIVIRAL IMMUNOTHERAPEUTICS.

  2023cites this paper
• Animal Models for the Investigation of P2X7 Receptors

  2023cites this paper
• Open resources for chemical probes and their implications for future drug discovery

  2023cites this paper
• Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists.

  2023cites this paper
• The role of the ATP-adenosine axis in ischemic stroke

  2023cites this paper
• Preparation of a Nanobody Specific to Dectin 1 and Its Anti-inflammatory Effects on Fungal Keratitis

  2022cites this paper
• A Possible Causal Involvement of Neuroinflammatory, Purinergic P2X7 Receptors in Psychiatric Disorders

  2022cites this paper
• Down the membrane hole: Ion channels in protozoan parasites

  2022cites this paper
• Origin, distribution, and function of three frequent coding polymorphisms in the gene for the human P2X7 ion channel

  2022influential citation
• Development of high-af fi nity nanobodies speci fi c for Na V 1.4 and Na V 1.5 voltage-gated sodium channel isoforms

  2022cites this paper
• CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy

  2022cites this paper
• Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo

  2022influential citation
• Nanobodies targeting LexA autocleavage disclose a novel suppression strategy of SOS-response pathway.

  2022cites this paper
• Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions

  2022influential citation
• Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs

  2022cites this paper
• P2X7 is expressed on human innate‐like T lymphocytes and mediates susceptibility to ATP‐induced cell death

  2022cites this paper
• Enhanced Transduction of P2X7-Expressing Cells with Recombinant rAAV Vectors.

  2022cites this paper
• Development of Antibody and Nanobody Tools for P2X7.

  2022cites this paper
• Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells

  2022cites this paper
• The Role of Microglial Purinergic Receptors in Pain Signaling

  2022cites this paper
• Nanobodies as molecular imaging probes.

  2022cites this paper
• Development of high-affinity nanobodies specific for NaV1.4 and NaV1.5 voltage-gated sodium channel isoforms

  2022cites this paper
• The P2X7 receptor as a new pharmacological target for retinal diseases.

  2022cites this paper
• P2X4 and P2X7 are essential players in basal T cell activity and Ca2+ signaling milliseconds after T cell activation

  2022cites this paper
• Immune response studies based on P2X7 receptors: A Mini-Review.

  2022cites this paper
• P2X7 receptor-specific radioligand 18F-FTTM for atherosclerotic plaque PET imaging

  2022cites this paper
• Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor

  2021cites this paper
• Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19)

  2021cites this paper
• The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization

  2021cites this paper
• The P2Y/P2X divide: how it began.

  2021cites this paper
• Increased expression of the ATP‐gated P2X7 receptor reduces responsiveness to anti‐convulsants during status epilepticus in mice

  2021cites this paper
• A comprehensive comparison between camelid nanobodies and single chain variable fragments

  2021cites this paper
• Structural basis of inhibition of a transporter from Staphylococcus aureus, NorC, through a single-domain camelid antibody

  2021cites this paper
• Antibody Therapies Targeting Complex Membrane Proteins

  2021cites this paper
• Nanobodies: new avenue to treat kidney disease

  2021cites this paper
• A simple, sensitive, and low‐cost FACS assay for detecting antibodies against the native SARS‐CoV‐2 spike protein

  2021cites this paper
• Controlling ion channel trafficking by targeted ubiquitination and deubiquitination.

  2021cites this paper
• Therapeutic Antibodies Targeting Potassium Ion Channels.

  2021cites this paper
• Construction of Synthetic Nanobody Library in Mammalian Cells by dsDNA‐Based Strategies **

  2021cites this paper
• OBSOLETE: Ion Channels

  2021cites this paper
• ADAM10-Mediated Ectodomain Shedding Is an Essential Driver of Podocyte Damage

  2021cites this paper
• Structural and Functional Features of the P2X4 Receptor: An Immunological Perspective

  2021cites this paper
• The P2X7 Receptor in Osteoarthritis

  2021cites this paper
• Functional P2X7 Receptors in the Auditory Nerve of Hearing Rodents Localize Exclusively to Peripheral Glia

  2021influential citation
• Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2

  2021cites this paper
• That was then, this is now: the development of our knowledge and understanding of P2 receptor subtypes

  2021cites this paper
• A Methodological Approach Using rAAV Vectors Encoding Nanobody-Based Biologics to Evaluate ARTC2.2 and P2X7 In Vivo

  2021cites this paper
• Nanobodies as probes to investigate purinergic signaling.

  2020cites this paper
• Flow Cytometry of Membrane Purinoreceptors.

  2020cites this paper
• The role of the P2X7 receptor in the renal vasculature in a mouse model of chronic kidney disease

  2020cites this paper
• P2X7 in Cancer: From Molecular Mechanisms to Therapeutics

  2020cites this paper
• Prospective Applications of Single-Domain Antibodies in Biomedicine

  2020cites this paper
• P2X7 Receptors as a Therapeutic Target in Cerebrovascular Diseases

  2020cites this paper
• The relationship between CD4+ follicular helper T cells and CD8+ resident memory T cells: sisters or distant cousins?

  2020cites this paper
• eATP/P2X7R Axis: An Orchestrated Pathway Triggering Inflammasome Activation in Muscle Diseases

  2020cites this paper
• Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano)

  2020influential citation
• Nanobodies: The Future of Antibody-Based Immune Therapeutics

  2020cites this paper
• NLRP3 Inflammasome and Allergic Contact Dermatitis: A Connection to Demystify

  2020cites this paper
• Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

  2020cites this paper
• P2X7 Receptors

  2020cites this paper
• Single-Domain Antibodies: Biology, Engineering and Emerging Applications

  2020cites this paper
• Animal models of pain: diversity and benefits.

  2020cites this paper
• Role of Conserved Residues and F322 in the Extracellular Vestibule of the Rat P2X7 Receptor in Its Expression, Function and Dye Uptake Ability

  2020cites this paper
• Nanobodies as Versatile Tool for Multiscale Imaging Modalities

  2020cites this paper
• P2X7 receptor and the NLRP3 inflammasome: partners in crime.

  2020cites this paper
• [Prospective Applications of Single-Domain Antibodies in Biomedicine].

  2020cites this paper